Nephropathy Clinical Trials in Beijing
15 recruitingBeijing, China
Showing 1–15 of 15 trials
Recruiting
Phase 2
Chinese Adults With Kidney Disease
Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 1
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd52 enrolled6 locationsNCT05668403
Recruiting
Phase 2Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Phase 2
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.30 enrolled40 locationsNCT07157787
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 1Phase 2
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Immunoglobulin A Nephropathy
Beijing Mabworks Biotech Co., Ltd.130 enrolled1 locationNCT07375758
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Lupus Nephritis (LN)Membranous Nephropathy
Shanghai Henlius Biotech24 enrolled17 locationsNCT07038382
Recruiting
Phase 1
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Primary Membranous Nephropathy
Everest Medicines (China) Co.,Ltd.30 enrolled19 locationsNCT05800873
Recruiting
Phase 2Phase 3
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd216 enrolled21 locationsNCT06470191
Recruiting
TESTING -ON Post-Trial ObservatioNal Cohort Study
Kidney DiseasesIgA NephropathyGlomerulonephritis+1 more
The George Institute366 enrolled58 locationsNCT05434325
Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Type 2 DiabetesDiabetic Kidney DiseaseDiabetic Nephropathy Type 2
Chinese PLA General Hospital2,000 enrolled1 locationNCT05888909